<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20190625044004N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-06-28</date_registration>
      <primary_sponsor>Ghoum University of Medical Sciences</primary_sponsor>
      <public_title>Comparative study of the effect of chamomile and flaxseed oil on patients with endometriosis</public_title>
      <acronym></acronym>
      <scientific_title>Comparative study of the effect of hydroalcoholic extract of chamomile and flaxseed oil on pelvic pain, dyspnea and dysmenorrhea in patients with endometriosis</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2019-12-01</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>108</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/40499</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this study, the limited randomization method of block randomization will be used. Blocking is usually used to balance the number of samples assigned to each of the study groups. This feature helps researchers to ensure that the number of samples assigned to each of the study groups is equal in cases where intermediate analyzes are required during the sampling process. The size of all the blocks is equal and in this
We will have a three-group trial of 36 blocks of 3. Randomization tool also uses random sequence generation software that these random sequence generation software in addition to simple randomization are able to generate random sequence by blocking method. For concealment, random allocation concealment is used, which is the method used to execute a random sequence on study participants, so that the assigned group is not known before the individual is assigned. Using opaque envelopes sealed with a random sequence in which each of the random sequences created on a card
It is registered and the cards are placed in the letter envelopes in order
To be. In order to maintain a random sequence, the envelopes are numbered in the same way on the outer surface. Finally, the lids of the letter envelopes are glued and placed inside a box, respectively. At the beginning of the sampling, one of the envelopes of the letter is opened and the assigned group of the participant is revealed, based on the order of entry of the eligible participants, Blinding description: Starting the treatment cycle, if the patient chooses code A, medication A is given and either B or C is given (for example A recipient of chamomile capsule and B code for flaxseed oil and C code for placebo). The coding is performed by a pharmacist.) The drugs are quite similar in appearance and are unknown to the researcher and patient, and are only known to the pharmacist but are quite similar in appearance. Each medication is packaged in separate packages coded with the letters A, B, and C and provided to research units.</study_design>
      <phase>3</phase>
      <hc_freetext>Endometriosis.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Chamomile -Dosage: 9 gr daily Dosage: 2 months- Frequency of use: In three divided doses (3 gr every 8 hours) How to use: Oral capsule - Producer: Pharmacist. Intervention 2: Intervention group: Flaxseed - Dosage: 6 gr daily Dosage: 2 months - Frequency: In three divided doses (2 gr every 8 hours) How to use: Oral capsule - Producer: Pharmacist. Intervention 3: Control Placebo - Dosage: 3 gr daily Dosage: 2 months - Dosage: In three divided doses (1 gr every 8 hours) How to use: Avicel oral capsule - Manufacturer: Pharmacistgroup:.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Individual data related to participants

When:
Start the access period 6 months after printing the results

To whom:
It will only be available to researchers working in academic and scientific institutions

Conditions:
Items that are in line with the studied variables

Where to obtain:
first name and last name: Fatemeh Mahnazadeh Fallahieh Email: mohana6492@gmail.com

How to obtain:
After requesting the email, the data will be sent within a week of the applicant's email

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Fatemeh Mohanazadehflaheieh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shahid Lavasani St. - Qom University of Medical Sciences and Health Services</address>
        <city>Qom</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3713649373</zip>
        <telephone>0098 2531071</telephone>
        <email>mohana6492@gmail.com</email>
        <affiliation>Ghoum University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Zohreh kalajinia</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shahid Lavasani St. - Qom University of Medical Sciences and Health Services</address>
        <city>Qom</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3713649373</zip>
        <telephone>0098 253107</telephone>
        <email>zkh6033@yahoo.com</email>
        <affiliation>Ghoum University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Married
Pelvic pain
dysmenorrhea
dysparonia
Hypovaccular mass and ultrasound vascular with varying degrees of blood flow velocity And the number of vessels seen in Doppler ultrasoundPatients
who referred to the Jihad Infertility Center of the University
Insensitivity to chamomile and flaxseed</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>45 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Has underlying heart, kidney, liver disease
Taking hormonal drugs such as oral contraceptive pills, progesterones</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>N80.1</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Endometriosis of ovary</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Chamomile -Dosage: 9 gr daily Dosage: 2 months- Frequency of use: In three divided doses (3 gr every 8 hours) How to use: Oral capsule - Producer: Pharmacist</i_keyword>
      <i_keyword>Intervention group: Flaxseed - Dosage: 6 gr daily Dosage: 2 months - Frequency: In three divided doses (2 gr every 8 hours) How to use: Oral capsule - Producer: Pharmacist</i_keyword>
      <i_keyword>Control Placebo - Dosage: 3 gr daily Dosage: 2 months - Dosage: In three divided doses (1 gr every 8 hours) How to use: Avicel oral capsule - Manufacturer: Pharmacistgroup:</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain score of people with dysmenorrhea. Timepoint: Measurement of reduction of dysmenorrhea before intervention and one month and two months after intervention After starting Consumption Chamomile and flaxseed oil and placebo. Method of measurement: Using Visual Analogue Scale.</prim_outcome>
      <prim_outcome>Pain score of people with chronic pelvic pain. Timepoint: Measurement of reduction of pelvic pain before intervention and one month and two months after intervention After starting Consumption Chamomile and flaxseed oil and placebo. Method of measurement: Using Visual Analogue Scale.</prim_outcome>
      <prim_outcome>Pain score of people with dysparonia. Timepoint: Measurement of reduction of dysdisparonia before intervention and one month and two months after intervention After starting Consumption Chamomile and flaxseed oil and placebo. Method of measurement: Using Visual Analogue Scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Ghoum University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-03-06</approval_date>
        <contact_name>Ethics committee of Qom University of Medical Sciences</contact_name>
        <contact_address>Shahid Lavasani St, Qom University of Medical Sciences Qom Ghoum Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
